Mortality benefit of isoniazid preventive therapy in HIV-positive persons: a simulation study [Short communication]

• Published in: The international journal of tuberculosis and lung disease Vol. 13; no. 8; pp. 1038 - 1040
• Main Authors: BACHHUBER, M. A, GROSS, R
• Format: Journal Article
• Language: English
• Published: Paris, France IUATLD 01-08-2009; International Union against Tuberculosis and Lung Disease
• Subjects: Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antitubercular Agents - therapeutic use; Bacterial diseases; Biological and medical sciences; Comorbidity; HIV; HIV Infections - epidemiology; Human bacterial diseases; Human immunodeficiency virus; Human viral diseases; Humans; Infectious diseases; isoniazid; Isoniazid - therapeutic use; Medical sciences; Meta-Analysis as Topic; Mortality; Mycobacterium; Pharmacology. Drug treatments; Pneumology; Respiratory system : syndromes and miscellaneous diseases; Tuberculosis; Tuberculosis - epidemiology; Tuberculosis - prevention & control; Tuberculosis and atypical mycobacterial infections; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Immunopathology; Prognosis; Respiratory disease; Mortality; Retroviridae; AIDS; Mycobacterial infection; Immune deficiency; Lentivirus; Epidemiology; Infection; Virus; Prevention; Treatment; Tuberculosis; Simulation; HIV; Viral disease; Bacteriosis; Antituberculous agent; Human immunodeficiency virus; Antibacterial agent; Isoniazid; Pneumology
• ISSN: 1027-3719; 1815-7920

A meta-analysis of isoniazid preventive therapy (IPT) in human immunodeficiency virus-positive individuals failed to show a mortality benefit even though tuberculosis is a leading cause of death in this group. Results for purified protein derivative (PPD) positive patients were heterogeneous,
however, and two of the included trials had many PPD-unknowns. When all PPD-unknowns were allocated to either PPD-positive or PPD-negative, the individual trial results were not robust, and simulated meta-analyses showed an overall reduction in all-cause mortality for PPD-positive individuals
on IPT (relative risk 0.76; 95% credibility interval 0.6-0.95).